The biology of neoadjuvant chemotherapy for breast cancer

Endocrine-Related Cancer

Volumn 9, Issue 3, 2002, Pages 183-195

  Cleator, S ^a   Parton, M ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISOLONE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE MARKER; DNA MICROARRAY; DRUG RESISTANCE; HUMAN; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IN SITU NICK-END LABELING; NEOADJUVANT THERAPY; PREMEDICATION; PREOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036749681     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090183     Document Type: Review

References (116)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA & Lonning PE 1996 Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2 811-814.
2. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M & Eudey L 1992 HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. Journal of Clinical Oncology 10 599-605.
3. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L & Borresen AL 1993 Prognostic significance of TP53 alterations in breast carcinoma. British Journal of Cancer 68 540-548.
4. Archer CD, Salter J, Hills M, Dowsett MD & Smith IE 1999 Induction of apoptosis and reduction in proliferation 24 hours after chemotherapy in early breast cancer. Procedings of the American Society of Clinical Oncologists 18 81A.
5. Assersohn L, Gangi L, Zhao Y, Dowsett M, Simon R, Powles TJ & Liu ET 2002 The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clinical Cancer Research 8 794-801.
6. Attardi LD & Jacks T 1999 The role of p53 in tumour suppression: lessons from mouse models. Cell Molecular Life Sciences 55 48-63.
7. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R & Taraboletti G 1996 The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clinical Cancer Research 2 1843-1849.
8. Berardo MD, Elledge RM, de Moor C, Clark GM, Osbome CK & Allred DC 1998 bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82 1296-1302.
9. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R & Rilke F 1990 Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. Journal of the National Cancer Institute 82 1539-1545.
10. Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M & Cetto GL 1996 Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Research and Treatment 38 289-297.
11. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F & Piubello Q 1998 bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research 4 2331-2336.
12. Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y, Asselain B & Pouillart P 1999 Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Research and Treatment 58 151-156.
13. Brown RW, Allred CD, Clark GM, Osborne CK & Hilsenbeck SG 1996 Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clinical Cancer Research 2 585-592.
14. Burkhart CA, Berman JW, Swindell CS & Horwitz SB 1994 Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Research 54 5779-5782.
15. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N et al. Fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. Journal of Clinical Oncology 17 3412-3417.
16. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK & Dowsett M 1999 Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal of Clinical Oncology 17 3058-3063.
17. Chen AY & Liu LF 1994 DNA topoisomerases: essential enzymes and lethal targets. Annual Review of Pharmacological Toxicology 34 191-218.
18. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H & Vielh P 1996 Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77 292-300.
19. Collecchi P, Baldini E, Giannessi P, Naccarato AG, Passoni A, Gardin G, Roncella M, Evangelista G, Bevilacqua G & Conte PF 1998 Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. European Journal of Cancer 34 1701-1704.
20. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G et al. 2000 Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Annals of Oncology 11 1057-1059.
21. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B et al. 2001 Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of Clinical Oncology 19 4141-4149.
22. Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, Brambilla C, Ferrari L & Silvestrini R 1999 Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. International Journal of Cancer 84 580-586.
23. van Der Hage JA, van De Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C & Duchateau L 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Journal of Clinical Oncology 19 4224-4237.
24. Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C & Wiemik PH 2000 20th-century advances in drug therapy in oncology - Part. II. Journal of Clinical Pharmacology 40 1079-1092.
25. Eastman A & Rigas JR 1999 Modulation of apoptosis signaling pathways and cell cycle regulation. Seminars in Oncology 26 7-16; discussion 41-12.
26. EBCTCG 1992 Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339 1-15.
27. Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE & Dowsett M 1997a Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer 76 480-485.
28. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R et al. 1997b Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. International Journal of Cancer 72 608-613.
29. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J & Dowsett M 1997c Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 349 849.
30. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR & Dowsett M 1998 Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Research and Treatment 48 107-116.
31. Fisher B, Gunduz N, Coyle J, Rudock C & Saffer E 1989a Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Research 49 1996-2001.
32. Fisher B, Saffer E, Rudock C, Coyle J & Gunduz N 1989b Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Research 49 2002-2004.
33. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N et al. 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of Clinical Oncology 15 2483-2493.
34. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16 2672-2685.
35. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L & Silingardi V 1997 Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Research and Treatment 44 185-192.
36. Gavrieli Y, Sherman Y & Ben-Sasson SA 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 119 493-501.
37. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA & Borresen-Dale AL 2001 Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research 61 2505-2512.
38. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U & Stein H 1984 Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology 133 1710-1715.
39. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R et al. 1992 Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology 10 1049-1056.
40. Hengartner MO 2000 The biochemistry of apoptosis. Nature 407 770-776,
41. Hickman JA 1992 Apoptosis induced by anticancer drugs. Cancer Metastasis Reviews 11 121-139.
42. Hickman JA, Beere HM, Wood AC, Waters CM & Parmar R 1992 Mechanisms of cytotoxicity caused by antitumour drugs. Toxicology Letters 64-65 553-561.
43. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK & Hortobagyi GN 1991 Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute 83 1797-1805.
44. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J & Pinedo HM 1998 Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British Journal of Cancer 77 621-626.
45. Hori M, Nogami T, Itabashi M, Yoshimi F, Ono H & Koizumi S 1997 Expression of Bcl-2 in human breast cancer: correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis. Pathology International 47 757-762.
46. Jia L, Srinivasula SM, Liu FT, Newland AC, Femandes-Alnemri T, Alnemri ES & Kelsey SM 2001 Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98 414-421.
47. Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M & Dowsett M 1999 Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Research 59 3646-3651.
48. Johnstone RW, Ruefli AA & Smyth MJ 2000 Multiple physiological functions for multidrug transporter P-glycoprotein? Trends in Biochemical Sciences 25 1-6.
49. Johnstone RW, Ruefli AA & Lowe SW 2002 Apoptosis. A Link between cancer genetics and chemotherapy. Cell 108 153-164.
50. Jordan MA, Toso RJ, Thrower D & Wilson L 1993 Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Procedings of the National Academy of Sciences of the USA 90 9552-9556.
51. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G et al. 2000 TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clinical Cancer Research 6 50-56.
52. Kartner N, Evernden-Porelle D, Bradley G & Ling V 1985 Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316 820-823.
53. Kerr JF, Winterford CM & Harmon BV 1994 Apoptosis. Its significance in cancer and cancer therapy. Cancer 73 2013-2026.
54. Khanna KK & Jackson SP 2001 DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genetics 27 247-254.
55. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S & Reed JC 1995 Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Research 55 4471-4478.
56. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H et al. 1999 Prognostic significance of apoptosis regulators in breast cancer. Endocrine-Related Cancer 6 29-40.
57. Lanni JS, Lowe SW, Licitra EJ, Liu JO & Jacks T 1997 p53-independent apoptosis induced by paclitaxel through an indirect mechanism. PNAS 94 9679-9683.
58. Ling V 1992 Charles F Kettering Prize: P-glycoprotein and resistance to anticancer drugs. Cancer 69 2603-2609.
59. Lipponen P, Aaltomaa S, Kosma VM & Syrjanen K 1994 Apoptosis in breast cancer as related to histopathological characteristics and prognosis. European Journal of Cancer 30A 2068-2073.
60. Liu R, Page C, Beidler DR, Wicha MS & Nunez G 1999 Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. American Journal of Pathology 155 1861-1867.
61. Liu S, Edgerton SM, Moore DH, 2nd & Thor AD 2001 Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clinical Cancer Research 7 1716-1723.
62. Lowe SW, Ruley HE, Jacks T & Housman DE 1993 p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 957-967.
63. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE & Jacks T 1994 p53 status and the efficacy of cancer therapy in vivo. Science 266 807-810.
64. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE Jr, Rosado M, Stewart V, Krishna S & Hindenburg AA 1989 Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Research 49 4120-4125.
65. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I & Coindre JM 1996 Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. British Journal of Cancer 74 1458-1465.
66. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC & Dowsett M 1998a Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Research and Treatment 48 11-20.
67. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG & Ford HT 1998b A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Annals of Oncology 9 1179-1184.
68. Mauriac L, Durand M, Avril A & Dilhuydy JM 1991 Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Annals of Oncology 2 347-354.
69. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM & Bonichon F 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Annals of Oncology 10 47-52.
70. Menard S, Fortis S, Castiglioni F, Agresti R & Balsari A 2001 HER2 as a prognostic factor in breast cancer. Oncology 61 67-72.
71. Miles DW, Harris WH, Gillett CE, Smith P & Barnes DM 1999 Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. International Journal of Cancer 84 354-359.
72. Moliterni A, Tarenzi E, Capri G, Terenziani M, Bertuzzi A, Grasselli G, Agresti R, Piotti P, Greco M, Salvadori B et al. 1997 Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Seminars in Oncology 24 S17-10-S17-14.
73. Niskanen E, Blomqvist C, Franssila K, Hietanen P & Wasenius VM 1997 Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. British Journal of Cancer 76 917-922.
74. NSABP 2001 The effect of primary tumour response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27. Breast Cancer Research and Treatment 69 210.
75. Orr MS, O'Connor PM & Kohn KW 2000 Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. Journal of the National Cancer Institute 92 987-994.
76. Overgaard J, Yilmaz M, Guldberg P, Hansen LL & Alsner J 2000 TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncologica 39 327-333.
77. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL & Wolmark N 1998 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute 90 1361-1370.
78. Parness J & Horwitz SB 1981 Taxol binds to polymerized tubulin in vitro. Journal of Cell Biology 91 479-487.
79. Parton MM, Archer C, Ashley S, Smith IE & Dowsett M 2001 Ki67/apoptotic index, a growth index for prediction of response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment 69 245.
80. Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R & Haegele P 2001 Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clinical Cancer Research 7 1577-1581.
81. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW & Ellis IO 1995 Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. British Journal of Cancer 71 146-149.
82. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D et al. 1995 Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology 13 547-552.
83. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M & Nenci I 1996 MIB-1 proliferative activity in invasive breast cancer measured by image analysis. Journal of Clinical Pathology 49 926-930.
84. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K & Nordling S 1997 Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncologica 36 369-374.
85. Reed JC 1997 Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Seminars in Hematology 34 9-19.
86. Reed JC 1999 Dysregulation of apoptosis in cancer. Journal of Clinical Oncology 17 2941-2953.
87. Revillion F, Hebbar M, Bonneterre J & Peyrat JP 1996 Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. European Journal of Cancer 32A 231-234.
88. Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ & Brousset P 1999 In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. Journal of Pathology 187 410-415.
89. Rowinsky EK, Donehower RC, Jones RJ & Tucker RW 1988 Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Research 48 4093-4100.
90. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V et al. 1998 No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. International Journal of Cancer 79 27-33.
91. Schiff PB & Horwitz SB 1980 Taxol stabilizes microtubules in mouse fibroblast cells. PNAS 77 1561-1565.
92. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P et al. 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. European Journal of Cancer 30A 645-652.
93. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM & Chepic OF 1994 Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Annals of Oncology 5 591-595.
94. Silvestrini R, Daidone MG & Gasparini G 1985 Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56 1982-1987.
95. Sjostrom J, Krajewski S, Franssila K, Niskanen E, Wasenius VM, Nordling S, Reed JC & Blomqvist C 1998 A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. British Journal of Cancer 78 812-815.
96. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 707-712.
97. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ & van de Vijver MJ 1996 Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. British Journal of Cancer 74 78-85.
98. van Slooten HJ, van de Vijver MJ, van de Velde CJ & van Dierendonck JH 1998 Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. British Journal of Cancer 77 789-796.
99. Smith PJ & Soues S 1994 Multilevel therapeutic targeting by topoisomerase inhibitors. British Journal of Cancer (Supplement) 23 S47-S51.
100. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK et al. 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology 20 1456-1466.
101. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich JP, Crow MT, Lakatta EG, Rowinsky EK et al. 1995 Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. Journal of Clinical Investigation 95 1869-1876.
102. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK & Liu ET 2002 Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research 4 R3.
103. Tamm I, Schriever F & Dorken B 2001 Apoptosis: implications of basic research for clinical oncology. Lancet Oncology 2 33-42.
104. Teixeira C, Reed JC & Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research 55 3902-3907.
105. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L & Liu ET 1998 erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 90 1346-1360.
106. Thor AD, Liu S, Moore DH, 2nd & Edgerton SM 1999 Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. Journal of Clinical Oncology 17 470-477.
107. Vakkala M, Lahteenmaki K, Raunio H, Paakko P & Soini Y 1999 Apoptosis during breast carcinoma progression. Clinical Cancer Research 5 319-324.
108. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT & Ciocca DR 1999 c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. International Journal of Cancer 84 129-134.
109. Verheij M & Bartelink H 2000 Radiation-induced apoptosis. Cell Tissue Research 301 133-142.
110. Vincent-Salomon A, Carton M, Freneaux P, Palangie T, Beuzeboc P, Mouret E, de Cremoux P, Coue O, Zafrani B, Nicolas A et al. 2000 ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. European Journal of Cancer 36 586-591.
111. Wallace-Brodeur RR & Lowe SW 1999 Clinical implications of p53 mutations. Cell Molecular Life Sciences 55 64-75.
112. Wijsman JH, Jonker RR, Keijzer R, van de Velde CJ, Cornelisse CJ & van Dierendonck JH 1993 A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. Journal of Histochemistry and Cytochemistry 41 7-12.
113. Willsher PC, Pinder SE, Gee JM, Ellis IO, Chan SY, Nicholson RI, Blamey RW & Robertson JF 1998 C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Research 18 3695-3698.
114. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U & von Kleist S 1991 Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67 421-428.
115. Yamauchi H, Stearns V & Hayes DF 2001 When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. Journal of Clinical Oncology 19 2334-2356.
116. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K & Tsuchiya A 1998 Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Research 18 1989-1998.